Baricitinib/cisatracurium besilate

Betotastine Besilate

The antiallergic activity of betotastine besilate was evaluated in comparison to that of other compounds in various rat models of allergy. Betotastine besilate inhibited histamine release from rat peritoneal mast cells and inhibited LTB4 and 5-HETE production in peritoneal cells at high concentrations (1 mM). Following oral administration at doses ranging from 0.1-30 mg/kg p.o., betotastine inh...

Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%

PURPOSE To examine the pooled per-protocol ocular end points from two conjunctival allergen challenge (CAC) clinical trials of the dual-action antihistamine bepotastine besilate ophthalmic solution (BBOS) 1.5%. METHODS Two Phase III, placebo-controlled, double-masked, randomized clinical trials were conducted at a total of six separate centers using the CAC model of allergic conjunctivitis. T...

Extract from the Clinical Evaluation Report for Olmesartan medoxomil, amlodipine (as besilate) and hydrochlorothiazide

Novel Functional Aspect of Antihistamines: The Impact of Bepotastine Besilate on Substance P-Induced Events

Besides histamine, substance P (SP) has been demonstrated to play a crucial role in pruritic skin diseases. Although antihistamines are frequently used for pruritic skin diseases, little is known concerning the effect on an SP-induced event such as mast cell degranulation and the upregulation of adhesion molecules or the nitric oxide (NO) synthesis in endothelial cells. Our aim was to study the...

Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis

Background Bepotastine besilate ophthalmic solution (BBOS) 1.5% is a topical antihistamine for the treatment of ocular itching associated with allergic conjunctivitis (AC). Allergic rhinitis and AC are common comorbid conditions. We explored the efficacy of BBOS 1.5% in alleviating nasal symptoms in an integrated analysis of two Phase III conjunctival allergen challenge (CAC) studies and a Phas...